What should the Defence innovation cell stop, start, accelerate, merge or defer across the portfolio connected to rapid experiment selection?
Innovation teams need to separate usable capability from demo theatre.
Answer block
What the page can settle.
Door
Portfolio prioritisation
Mapped to the Enter Evidence Pack route.
Buyer
Defence innovation cell
2-star/director, SRO, transformation lead, prime programme director, national programme office
Fit
How Lansary reads it.
DEE structures evidence and uncertainty around rapid experiment selection into decision-ready options.
First step
Portfolio trade matrix, stop/start recommendations, dependency view
Sell as a portfolio-prioritisation engagement.
Start with named public records.
- https://www.nato.int/en/what-we-do/introduction-to-nato/defence-expenditures-and-natos-5-commitment
- https://www.gov.uk/government/publications/the-strategic-defence-review-2025-making-britain-safer-secure-at-home-strong-abroad
- https://www.gov.uk/government/publications/defence-industrial-strategy-2025-making-defence-an-engine-for-growth
This page is a routing surface. The private Evidence Pack tests the named subject, dates, source boundary and decision consequence.